Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography–tandem mass spectrometry
•Our HPLC–MS/MS assay is accurate, robust and highly selective.•The limit of detection of 30pg/mL for all analytes.•Analytical method suitable to conduct PK studies using a small single dose of OXY.•Our assay permits a proper characterization of half-life.•Our assay would determine precisely PK para...
Saved in:
| Published in | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 1008; pp. 174 - 180 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.01.2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1570-0232 1873-376X 1873-376X |
| DOI | 10.1016/j.jchromb.2015.11.035 |
Cover
| Abstract | •Our HPLC–MS/MS assay is accurate, robust and highly selective.•The limit of detection of 30pg/mL for all analytes.•Analytical method suitable to conduct PK studies using a small single dose of OXY.•Our assay permits a proper characterization of half-life.•Our assay would determine precisely PK parameters in CYP2D6 EM and PM subpopulations.
Oxycodone is an opioid agonist largely prescribed for the treatment of moderate to severe pain. Variability in analgesic efficacy could be explained by inter-subject variations in plasma levels of parent drug and its active metabolite, oxymorphone. For this purpose it is necessary to develop and validate a sensitive and selective analytical method for the quantification of oxycodone and its major metabolites, noroxycodone and oxymorphone, in human plasma. The analytical method consisted of a liquid–liquid extraction procedure followed by a high performance liquid chromatography with heated assisted electrospray ionization mass spectrometry (HPLC–HESI–MS/MS). The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.The calibration functions are linear in the range of 300–50,000pg/mL for oxycodone and noroxycodone and 50 to 10 000pg/mL for oxymorphone. Intra- and inter-day relative standard deviations are less than 5.5% and 6.4%, respectively for all analytes. The limit of detection was 30pg/mL for all analytes. We introduce a new HPLC–HESI–MS/MS sensitive and specific analytical method capable to simultaneously quantify oxycodone, noroxycodone and oxymorphone, in human plasma, and suitable for the conduct of pharmacokinetic studies after a single dose administration of the parent compound. |
|---|---|
| AbstractList | Oxycodone is an opioid agonist largely prescribed for the treatment of moderate to severe pain. Variability in analgesic efficacy could be explained by inter-subject variations in plasma levels of parent drug and its active metabolite, oxymorphone. For this purpose it is necessary to develop and validate a sensitive and selective analytical method for the quantification of oxycodone and its major metabolites, noroxycodone and oxymorphone, in human plasma. The analytical method consisted of a liquid-liquid extraction procedure followed by a high performance liquid chromatography with heated assisted electrospray ionization mass spectrometry (HPLC-HESI-MS/MS). The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.The calibration functions are linear in the range of 300-50,000pg/mL for oxycodone and noroxycodone and 50 to 10 000pg/mL for oxymorphone. Intra- and inter-day relative standard deviations are less than 5.5% and 6.4%, respectively for all analytes. The limit of detection was 30pg/mL for all analytes. We introduce a new HPLC-HESI-MS/MS sensitive and specific analytical method capable to simultaneously quantify oxycodone, noroxycodone and oxymorphone, in human plasma, and suitable for the conduct of pharmacokinetic studies after a single dose administration of the parent compound.Oxycodone is an opioid agonist largely prescribed for the treatment of moderate to severe pain. Variability in analgesic efficacy could be explained by inter-subject variations in plasma levels of parent drug and its active metabolite, oxymorphone. For this purpose it is necessary to develop and validate a sensitive and selective analytical method for the quantification of oxycodone and its major metabolites, noroxycodone and oxymorphone, in human plasma. The analytical method consisted of a liquid-liquid extraction procedure followed by a high performance liquid chromatography with heated assisted electrospray ionization mass spectrometry (HPLC-HESI-MS/MS). The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.The calibration functions are linear in the range of 300-50,000pg/mL for oxycodone and noroxycodone and 50 to 10 000pg/mL for oxymorphone. Intra- and inter-day relative standard deviations are less than 5.5% and 6.4%, respectively for all analytes. The limit of detection was 30pg/mL for all analytes. We introduce a new HPLC-HESI-MS/MS sensitive and specific analytical method capable to simultaneously quantify oxycodone, noroxycodone and oxymorphone, in human plasma, and suitable for the conduct of pharmacokinetic studies after a single dose administration of the parent compound. •Our HPLC–MS/MS assay is accurate, robust and highly selective.•The limit of detection of 30pg/mL for all analytes.•Analytical method suitable to conduct PK studies using a small single dose of OXY.•Our assay permits a proper characterization of half-life.•Our assay would determine precisely PK parameters in CYP2D6 EM and PM subpopulations. Oxycodone is an opioid agonist largely prescribed for the treatment of moderate to severe pain. Variability in analgesic efficacy could be explained by inter-subject variations in plasma levels of parent drug and its active metabolite, oxymorphone. For this purpose it is necessary to develop and validate a sensitive and selective analytical method for the quantification of oxycodone and its major metabolites, noroxycodone and oxymorphone, in human plasma. The analytical method consisted of a liquid–liquid extraction procedure followed by a high performance liquid chromatography with heated assisted electrospray ionization mass spectrometry (HPLC–HESI–MS/MS). The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.The calibration functions are linear in the range of 300–50,000pg/mL for oxycodone and noroxycodone and 50 to 10 000pg/mL for oxymorphone. Intra- and inter-day relative standard deviations are less than 5.5% and 6.4%, respectively for all analytes. The limit of detection was 30pg/mL for all analytes. We introduce a new HPLC–HESI–MS/MS sensitive and specific analytical method capable to simultaneously quantify oxycodone, noroxycodone and oxymorphone, in human plasma, and suitable for the conduct of pharmacokinetic studies after a single dose administration of the parent compound. Oxycodone is an opioid agonist largely prescribed for the treatment of moderate to severe pain. Variability in analgesic efficacy could be explained by inter-subject variations in plasma levels of parent drug and its active metabolite, oxymorphone. For this purpose it is necessary to develop and validate a sensitive and selective analytical method for the quantification of oxycodone and its major metabolites, noroxycodone and oxymorphone, in human plasma. The analytical method consisted of a liquid-liquid extraction procedure followed by a high performance liquid chromatography with heated assisted electrospray ionization mass spectrometry (HPLC-HESI-MS/MS). The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.The calibration functions are linear in the range of 300-50,000pg/mL for oxycodone and noroxycodone and 50 to 10 000pg/mL for oxymorphone. Intra- and inter-day relative standard deviations are less than 5.5% and 6.4%, respectively for all analytes. The limit of detection was 30pg/mL for all analytes. We introduce a new HPLC-HESI-MS/MS sensitive and specific analytical method capable to simultaneously quantify oxycodone, noroxycodone and oxymorphone, in human plasma, and suitable for the conduct of pharmacokinetic studies after a single dose administration of the parent compound. |
| Author | Gaudette, Fleur Turgeon, Jacques Michaud, Veronique Sirhan-Daneau, Andréa St-Onge, Maude |
| Author_xml | – sequence: 1 givenname: Fleur surname: Gaudette fullname: Gaudette, Fleur organization: CRCHUM, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada – sequence: 2 givenname: Andréa surname: Sirhan-Daneau fullname: Sirhan-Daneau, Andréa organization: CRCHUM, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada – sequence: 3 givenname: Maude surname: St-Onge fullname: St-Onge, Maude organization: CRCHUM, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada – sequence: 4 givenname: Jacques surname: Turgeon fullname: Turgeon, Jacques organization: CRCHUM, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada – sequence: 5 givenname: Veronique surname: Michaud fullname: Michaud, Veronique email: v.michaud@umontreal.ca, veronique.michaud.chum@ssss.gouv.qc.ca organization: CRCHUM, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26655109$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkkuO1DAQhiM0iHnAEUBeskmw446diAVCw1MaiQ1I7Cy3XSGOYjtjO63JjjtwIO7CSXBP9yxg0yu7VN9fZVf9l8WZ8w6K4jnBFcGEvRqrUQ3B221VY9JUhFSYNo-KC9JyWlLOvp_le8NxiWtanxeXMY4YE445fVKc14w1DcHdRfH7Hexg8rMFl5DvkUQRXDTJ7ABZSIPXqPcBpQGQhgTBGieT8W7P-rtVeZ2fhaTTyKSIrBwznHVy6yeTICLnw79YjqwP87CPjUPDYqVD8ySjlWi7osncLkaj-6_J5H8EOQ_rn5-_UtaCzQ1iRHEGlXIeUlifFo97OUV4djyvim8f3n-9_lTefPn4-frtTalo16YS8EZK6GnHupZL1jHes5Z2Nd0ozFnHO9KQltRcbYjmUKteZazlus_pTrWSXhUvD3Xn4G8XiElYExVMk3TglyhqjDHd0JbzkyjhDcV5-B3L6IsjumwtaDEHY2VYxcN-MvD6AKjgYwzQC2XS_QJSkGYSBIu9G8Qojm4QezcIQkR2Q1Y3_6kfGpzSvTnoIE90ZyCIqAw4BdqEPHqhvTlR4S_tPNgg |
| CitedBy_id | crossref_primary_10_1039_C9RA05785D crossref_primary_10_1016_j_jpha_2018_01_006 crossref_primary_10_1149_2_0511914jes crossref_primary_10_1016_j_jchromb_2019_04_044 crossref_primary_10_1002_bmc_5874 crossref_primary_10_1002_dta_2660 crossref_primary_10_1016_j_microc_2021_105988 crossref_primary_10_1039_D1NJ03344A crossref_primary_10_1515_cclm_2016_0990 crossref_primary_10_1093_jat_bkaa051 crossref_primary_10_1093_jat_bkaa186 crossref_primary_10_1007_s00604_020_04655_3 crossref_primary_10_1038_s41598_024_68310_0 crossref_primary_10_3390_pharmaceutics13091466 |
| Cites_doi | 10.1111/j.1476-5381.2010.00709.x 10.1002/jms.1021 10.1097/FTD.0b013e31816e2d4b 10.1016/S0090-9556(25)08048-1 10.1007/s40265-013-0036-0 10.1111/j.1399-6576.1986.tb02487.x 10.1016/S0009-9236(98)90051-0 10.1016/j.jchromb.2004.10.035 10.1016/j.clpt.2006.01.009 10.1111/j.1742-7843.2009.00378.x 10.1016/S0885-3924(98)00064-5 10.1371/journal.pone.0060239 10.1016/S0009-9236(96)90024-7 10.1111/j.1476-5381.2010.00673.x 10.1016/j.jpainsymman.2005.01.010 10.1007/s00520-002-0385-9 10.1124/dmd.32.4.447 10.1007/s00228-011-1093-5 10.1016/S0022-3565(25)24040-X 10.1177/009127007701700402 10.1002/rcm.1658 10.1016/j.jchromb.2010.01.014 10.1016/0952-8180(95)00092-5 10.1517/17425255.2013.779669 10.1093/jat/bkt042 10.1097/JCP.0b013e3182189892 10.1111/j.1399-6576.2009.02104.x 10.1016/j.forsciint.2009.12.005 10.1111/j.1365-2125.1992.tb04090.x |
| ContentType | Journal Article |
| Copyright | 2015 Elsevier B.V. Copyright © 2015 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2015 Elsevier B.V. – notice: Copyright © 2015 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 |
| DOI | 10.1016/j.jchromb.2015.11.035 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1873-376X |
| EndPage | 180 |
| ExternalDocumentID | 26655109 10_1016_j_jchromb_2015_11_035 S1570023215302993 |
| Genre | Validation Studies Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AAXUO ABFRF ABGSF ABJNI ABMAC ABUDA ABYKQ ACDAQ ACGFS ACRLP ADBBV ADECG ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AFKWA AFTJW AFXIZ AFZHZ AGHFR AGUBO AGYEJ AI. AIEXJ AIKHN AITUG AJBFU AJOXV AJSZI ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC CS3 DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FLBIZ FNPLU FYGXN G-Q GBLVA HVGLF IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 PC. Q38 RIG RNS ROL RPZ SCB SCC SDF SDG SDP SES SPC SPCBC SSK SSU SSZ T5K VH1 ~G- .GJ 29K AATTM AAXKI AAYWO AAYXX ABFNM ABXDB ACNNM AEIPS AFJKZ AGCQF AGRDE AGRNS AIIUN ANKPU APXCP BNPGV CITATION D-I HZ~ OHT SEW SSH ZGI CGR CUY CVF ECM EFKBS EIF NPM 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c398t-e04aaef396987a6967f6839234c0769791518127c41d7e2cfc87a87dfc079c8a3 |
| IEDL.DBID | AIKHN |
| ISSN | 1570-0232 1873-376X |
| IngestDate | Thu Sep 04 15:06:15 EDT 2025 Thu Sep 04 23:30:44 EDT 2025 Mon Jul 21 05:57:07 EDT 2025 Thu Jul 03 08:24:02 EDT 2025 Thu Apr 24 23:10:28 EDT 2025 Fri Feb 23 02:19:34 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Human Plasma Oxycodone Noroxycodone Liquid chromatography Mass spectrometry Oxymorphone |
| Language | English |
| License | Copyright © 2015 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c398t-e04aaef396987a6967f6839234c0769791518127c41d7e2cfc87a87dfc079c8a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 26655109 |
| PQID | 1753010996 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2000343877 proquest_miscellaneous_1753010996 pubmed_primary_26655109 crossref_citationtrail_10_1016_j_jchromb_2015_11_035 crossref_primary_10_1016_j_jchromb_2015_11_035 elsevier_sciencedirect_doi_10_1016_j_jchromb_2015_11_035 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-01 2016-01-00 2016-Jan-01 20160101 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences |
| PublicationTitleAlternate | J Chromatogr B Analyt Technol Biomed Life Sci |
| PublicationYear | 2016 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Davis (bib0010) 2003; 11 Poyhia (bib0030) 1992; 33 Bostrom (bib0135) 2004; 18 Samer (bib0085) 2010; 160 Zwisler (bib0090) 2010; 54 Samer (bib0065) 2010; 160 Edwards, Moore, McQuay (bib0025) 2000; 4 Nuutinen, Wuolijoki, Pentikainen (bib0015) 1986; 30 Heiskanen, Olkkola, Kalso (bib0070) 1998; 64 Musshoff (bib0140) 2006; 41 Parris (bib0020) 1998; 16 Kirvela (bib0035) 1996; 8 Lalovic (bib0045) 2006; 79 Liukas (bib0105) 2011; 31 Beaver (bib0060) 1977; 17 Zwisler (bib0110) 2009; 104 Andreassen (bib0100) 2012; 68 Kaiko (bib0150) 1996; 59 Klimas (bib0095) 2013; 9 FDA Guidance, US. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), (2001) Guidance for Industry. Bioanalytical Method Validation. Available at Fang (bib0130) 2013; 37 Lalovic (bib0040) 2004; 32 Neuvonen, Neuvonen (bib0115) 2008; 30 . Cone (bib0125) 2010; 198 Wagner (bib0155) 2010; 878 Soderberg Lofdal, Andersson, Gustafsson (bib0075) 2013; 73 Cleary (bib0055) 1994; 271 Cone (bib0050) 1983; 11 Edwards, Smith (bib0120) 2005; 814 Stamer (bib0080) 2013; 8 Kalso (bib0005) 2005; 29 Kaiko (10.1016/j.jchromb.2015.11.035_bib0150) 1996; 59 10.1016/j.jchromb.2015.11.035_bib0145 Samer (10.1016/j.jchromb.2015.11.035_bib0065) 2010; 160 Neuvonen (10.1016/j.jchromb.2015.11.035_bib0115) 2008; 30 Heiskanen (10.1016/j.jchromb.2015.11.035_bib0070) 1998; 64 Parris (10.1016/j.jchromb.2015.11.035_bib0020) 1998; 16 Kalso (10.1016/j.jchromb.2015.11.035_bib0005) 2005; 29 Cone (10.1016/j.jchromb.2015.11.035_bib0125) 2010; 198 Poyhia (10.1016/j.jchromb.2015.11.035_bib0030) 1992; 33 Andreassen (10.1016/j.jchromb.2015.11.035_bib0100) 2012; 68 Lalovic (10.1016/j.jchromb.2015.11.035_bib0045) 2006; 79 Samer (10.1016/j.jchromb.2015.11.035_bib0085) 2010; 160 Beaver (10.1016/j.jchromb.2015.11.035_bib0060) 1977; 17 Edwards (10.1016/j.jchromb.2015.11.035_bib0120) 2005; 814 Cleary (10.1016/j.jchromb.2015.11.035_bib0055) 1994; 271 Fang (10.1016/j.jchromb.2015.11.035_bib0130) 2013; 37 Musshoff (10.1016/j.jchromb.2015.11.035_bib0140) 2006; 41 Soderberg Lofdal (10.1016/j.jchromb.2015.11.035_bib0075) 2013; 73 Klimas (10.1016/j.jchromb.2015.11.035_bib0095) 2013; 9 Bostrom (10.1016/j.jchromb.2015.11.035_bib0135) 2004; 18 Liukas (10.1016/j.jchromb.2015.11.035_bib0105) 2011; 31 Edwards (10.1016/j.jchromb.2015.11.035_bib0025) 2000; 4 Cone (10.1016/j.jchromb.2015.11.035_bib0050) 1983; 11 Zwisler (10.1016/j.jchromb.2015.11.035_bib0090) 2010; 54 Lalovic (10.1016/j.jchromb.2015.11.035_bib0040) 2004; 32 Zwisler (10.1016/j.jchromb.2015.11.035_bib0110) 2009; 104 Kirvela (10.1016/j.jchromb.2015.11.035_bib0035) 1996; 8 Nuutinen (10.1016/j.jchromb.2015.11.035_bib0015) 1986; 30 Davis (10.1016/j.jchromb.2015.11.035_bib0010) 2003; 11 Stamer (10.1016/j.jchromb.2015.11.035_bib0080) 2013; 8 Wagner (10.1016/j.jchromb.2015.11.035_bib0155) 2010; 878 |
| References_xml | – volume: 33 start-page: 617 year: 1992 end-page: 621 ident: bib0030 article-title: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects publication-title: Br. J. Clin. Pharmacol. – volume: 271 start-page: 1528 year: 1994 end-page: 1534 ident: bib0055 article-title: The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model publication-title: J. Pharmacol. Exp. Ther. – volume: 79 start-page: 461 year: 2006 end-page: 479 ident: bib0045 article-title: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites publication-title: Clin. Pharmacol. Ther. – volume: 104 start-page: 335 year: 2009 end-page: 344 ident: bib0110 article-title: The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism publication-title: Basic Clin. Pharmacol. Toxicol. – volume: 11 start-page: 446 year: 1983 end-page: 450 ident: bib0050 article-title: Oxymorphone metabolism and urinary excretion in human: rat, guinea pig, rabbit, and dog publication-title: Drug Metab. Dispos. – volume: 30 start-page: 333 year: 2008 end-page: 340 ident: bib0115 article-title: Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray–tandem mass spectrometry publication-title: Ther. Drug Monit. – volume: 32 start-page: 447 year: 2004 end-page: 454 ident: bib0040 article-title: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes publication-title: Drug Metab. Dispos. – volume: 160 start-page: 907 year: 2010 end-page: 918 ident: bib0065 article-title: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone publication-title: Br. J. Pharmacol. – volume: 54 start-page: 232 year: 2010 end-page: 240 ident: bib0090 article-title: Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia publication-title: Acta Anaesthesiol. Scand. – volume: 59 start-page: 52 year: 1996 end-page: 61 ident: bib0150 article-title: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone publication-title: Clin. Pharmacol. Ther. – volume: 31 start-page: 302 year: 2011 end-page: 308 ident: bib0105 article-title: Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers publication-title: J. Clin. Psychopharmacol. – volume: 814 start-page: 241 year: 2005 end-page: 249 ident: bib0120 article-title: Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – volume: 29 start-page: S47 year: 2005 end-page: 56 ident: bib0005 article-title: Oxycodone publication-title: J. Pain Symptom Manage. – volume: 11 start-page: 84 year: 2003 end-page: 92 ident: bib0010 article-title: Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy publication-title: Support. Care Cancer – volume: 30 start-page: 620 year: 1986 end-page: 624 ident: bib0015 article-title: Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial publication-title: Acta Anaesthesiol. Scand. – volume: 4 start-page: CD002763 year: 2000 ident: bib0025 article-title: Single dose oxycodone and oxycodone plus paracetamol (acetominophen) for acute postoperative pain publication-title: Cochrane Database Syst. Rev. – volume: 64 start-page: 603 year: 1998 end-page: 611 ident: bib0070 article-title: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone publication-title: Clin. Pharmacol. Ther. – volume: 18 start-page: 2565 year: 2004 end-page: 2576 ident: bib0135 article-title: The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone: oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue publication-title: Rapid Commun. Mass Spectrom. – reference: FDA Guidance, US. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), (2001) Guidance for Industry. Bioanalytical Method Validation. Available at: – volume: 8 start-page: 13 year: 1996 end-page: 18 ident: bib0035 article-title: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation publication-title: J. Clin. Anesth. – volume: 37 start-page: 337 year: 2013 end-page: 344 ident: bib0130 article-title: Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications publication-title: J. Anal. Toxicol. – volume: 17 start-page: 186 year: 1977 end-page: 198 ident: bib0060 article-title: Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer publication-title: J. Clin. Pharmacol. – volume: 9 start-page: 517 year: 2013 end-page: 528 ident: bib0095 article-title: Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration publication-title: Expert Opin. Drug Metab. Toxicol. – volume: 878 start-page: 637 year: 2010 end-page: 644 ident: bib0155 article-title: Quantitation of polar analytes using column-switching: application to oxycodone and three metabolites in human plasma publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – reference: . – volume: 73 start-page: 533 year: 2013 end-page: 543 ident: bib0075 article-title: Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications publication-title: Drugs – volume: 16 start-page: 205 year: 1998 end-page: 211 ident: bib0020 article-title: The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study publication-title: J. Pain Symptom Manage. – volume: 160 start-page: 919 year: 2010 end-page: 930 ident: bib0085 article-title: Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety publication-title: Br. J. Pharmacol. – volume: 8 start-page: e60239 year: 2013 ident: bib0080 article-title: CYP2D6 genotype dependent oxycodone metabolism in postoperative patients publication-title: PLoS One – volume: 68 start-page: 55 year: 2012 end-page: 64 ident: bib0100 article-title: Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study publication-title: Eur. J. Clin. Pharmacol. – volume: 198 start-page: 58 year: 2010 end-page: 61 ident: bib0125 article-title: Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives publication-title: Forensic Sci. Int – volume: 41 start-page: 633 year: 2006 end-page: 640 ident: bib0140 article-title: An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care: with 5 of their metabolites publication-title: J. Mass Spectrom. – volume: 160 start-page: 919 issue: 4 year: 2010 ident: 10.1016/j.jchromb.2015.11.035_bib0085 article-title: Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2010.00709.x – volume: 41 start-page: 633 issue: 5 year: 2006 ident: 10.1016/j.jchromb.2015.11.035_bib0140 article-title: An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care: with 5 of their metabolites publication-title: J. Mass Spectrom. doi: 10.1002/jms.1021 – volume: 30 start-page: 333 issue: 3 year: 2008 ident: 10.1016/j.jchromb.2015.11.035_bib0115 article-title: Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray–tandem mass spectrometry publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0b013e31816e2d4b – ident: 10.1016/j.jchromb.2015.11.035_bib0145 – volume: 4 start-page: CD002763 year: 2000 ident: 10.1016/j.jchromb.2015.11.035_bib0025 article-title: Single dose oxycodone and oxycodone plus paracetamol (acetominophen) for acute postoperative pain publication-title: Cochrane Database Syst. Rev. – volume: 11 start-page: 446 issue: 5 year: 1983 ident: 10.1016/j.jchromb.2015.11.035_bib0050 article-title: Oxymorphone metabolism and urinary excretion in human: rat, guinea pig, rabbit, and dog publication-title: Drug Metab. Dispos. doi: 10.1016/S0090-9556(25)08048-1 – volume: 73 start-page: 533 issue: 6 year: 2013 ident: 10.1016/j.jchromb.2015.11.035_bib0075 article-title: Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications publication-title: Drugs doi: 10.1007/s40265-013-0036-0 – volume: 30 start-page: 620 issue: 8 year: 1986 ident: 10.1016/j.jchromb.2015.11.035_bib0015 article-title: Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial publication-title: Acta Anaesthesiol. Scand. doi: 10.1111/j.1399-6576.1986.tb02487.x – volume: 64 start-page: 603 issue: 6 year: 1998 ident: 10.1016/j.jchromb.2015.11.035_bib0070 article-title: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone publication-title: Clin. Pharmacol. Ther. doi: 10.1016/S0009-9236(98)90051-0 – volume: 814 start-page: 241 issue: 2 year: 2005 ident: 10.1016/j.jchromb.2015.11.035_bib0120 article-title: Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2004.10.035 – volume: 79 start-page: 461 issue: 5 year: 2006 ident: 10.1016/j.jchromb.2015.11.035_bib0045 article-title: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites publication-title: Clin. Pharmacol. Ther. doi: 10.1016/j.clpt.2006.01.009 – volume: 104 start-page: 335 issue: 4 year: 2009 ident: 10.1016/j.jchromb.2015.11.035_bib0110 article-title: The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism publication-title: Basic Clin. Pharmacol. Toxicol. doi: 10.1111/j.1742-7843.2009.00378.x – volume: 16 start-page: 205 issue: 4 year: 1998 ident: 10.1016/j.jchromb.2015.11.035_bib0020 article-title: The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study publication-title: J. Pain Symptom Manage. doi: 10.1016/S0885-3924(98)00064-5 – volume: 8 start-page: e60239 issue: 3 year: 2013 ident: 10.1016/j.jchromb.2015.11.035_bib0080 article-title: CYP2D6 genotype dependent oxycodone metabolism in postoperative patients publication-title: PLoS One doi: 10.1371/journal.pone.0060239 – volume: 59 start-page: 52 issue: 1 year: 1996 ident: 10.1016/j.jchromb.2015.11.035_bib0150 article-title: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone publication-title: Clin. Pharmacol. Ther. doi: 10.1016/S0009-9236(96)90024-7 – volume: 160 start-page: 907 issue: 4 year: 2010 ident: 10.1016/j.jchromb.2015.11.035_bib0065 article-title: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2010.00673.x – volume: 29 start-page: S47 issue: Suppl. 5 year: 2005 ident: 10.1016/j.jchromb.2015.11.035_bib0005 article-title: Oxycodone publication-title: J. Pain Symptom Manage. doi: 10.1016/j.jpainsymman.2005.01.010 – volume: 11 start-page: 84 issue: 2 year: 2003 ident: 10.1016/j.jchromb.2015.11.035_bib0010 article-title: Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy publication-title: Support. Care Cancer doi: 10.1007/s00520-002-0385-9 – volume: 32 start-page: 447 issue: 4 year: 2004 ident: 10.1016/j.jchromb.2015.11.035_bib0040 article-title: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.32.4.447 – volume: 68 start-page: 55 issue: 1 year: 2012 ident: 10.1016/j.jchromb.2015.11.035_bib0100 article-title: Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/s00228-011-1093-5 – volume: 271 start-page: 1528 issue: 3 year: 1994 ident: 10.1016/j.jchromb.2015.11.035_bib0055 article-title: The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(25)24040-X – volume: 17 start-page: 186 issue: 4 year: 1977 ident: 10.1016/j.jchromb.2015.11.035_bib0060 article-title: Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer publication-title: J. Clin. Pharmacol. doi: 10.1177/009127007701700402 – volume: 18 start-page: 2565 issue: 21 year: 2004 ident: 10.1016/j.jchromb.2015.11.035_bib0135 article-title: The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone: oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue publication-title: Rapid Commun. Mass Spectrom. doi: 10.1002/rcm.1658 – volume: 878 start-page: 637 issue: 7–8 year: 2010 ident: 10.1016/j.jchromb.2015.11.035_bib0155 article-title: Quantitation of polar analytes using column-switching: application to oxycodone and three metabolites in human plasma publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2010.01.014 – volume: 8 start-page: 13 issue: 1 year: 1996 ident: 10.1016/j.jchromb.2015.11.035_bib0035 article-title: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation publication-title: J. Clin. Anesth. doi: 10.1016/0952-8180(95)00092-5 – volume: 9 start-page: 517 issue: 5 year: 2013 ident: 10.1016/j.jchromb.2015.11.035_bib0095 article-title: Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425255.2013.779669 – volume: 37 start-page: 337 issue: 6 year: 2013 ident: 10.1016/j.jchromb.2015.11.035_bib0130 article-title: Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications publication-title: J. Anal. Toxicol. doi: 10.1093/jat/bkt042 – volume: 31 start-page: 302 issue: 3 year: 2011 ident: 10.1016/j.jchromb.2015.11.035_bib0105 article-title: Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers publication-title: J. Clin. Psychopharmacol. doi: 10.1097/JCP.0b013e3182189892 – volume: 54 start-page: 232 issue: 2 year: 2010 ident: 10.1016/j.jchromb.2015.11.035_bib0090 article-title: Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia publication-title: Acta Anaesthesiol. Scand. doi: 10.1111/j.1399-6576.2009.02104.x – volume: 198 start-page: 58 issue: 1–3 year: 2010 ident: 10.1016/j.jchromb.2015.11.035_bib0125 article-title: Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives publication-title: Forensic Sci. Int doi: 10.1016/j.forsciint.2009.12.005 – volume: 33 start-page: 617 issue: 6 year: 1992 ident: 10.1016/j.jchromb.2015.11.035_bib0030 article-title: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.1992.tb04090.x |
| SSID | ssj0017073 |
| Score | 2.2518234 |
| Snippet | •Our HPLC–MS/MS assay is accurate, robust and highly selective.•The limit of detection of 30pg/mL for all analytes.•Analytical method suitable to conduct PK... Oxycodone is an opioid agonist largely prescribed for the treatment of moderate to severe pain. Variability in analgesic efficacy could be explained by... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 174 |
| SubjectTerms | agonists ammonium acetate analgesics Chromatography, Liquid - methods detection limit electrospray ionization mass spectrometry ethanol high performance liquid chromatography Human Humans Limit of Detection Liquid chromatography liquid-liquid extraction Mass spectrometry metabolites Morphinans - blood Noroxycodone Oxycodone Oxycodone - blood Oxymorphone Oxymorphone - blood pharmacokinetics Plasma Reproducibility of Results statistical analysis tandem mass spectrometry Tandem Mass Spectrometry - methods |
| Title | Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography–tandem mass spectrometry |
| URI | https://dx.doi.org/10.1016/j.jchromb.2015.11.035 https://www.ncbi.nlm.nih.gov/pubmed/26655109 https://www.proquest.com/docview/1753010996 https://www.proquest.com/docview/2000343877 |
| Volume | 1008 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF616YULAsojPKJBQtyc-BWv9xhFVOFVIaBSb9Z6vRaOaju1HYlcEP-BH8R_4Zcws14HKlFV4mhnRhl5Zme-3Z0HYy94mKsUQ5EjAu076PBcJ8Yo40RZEKU0ZtINqd75_Wm0OgvfnM_PD9hyqIWhtErr-3ufbry1fTOzX3O2KYrZJ49asyMg8GjwDYbZQ3bkByKaj9jR4vXb1en-MoG75qKZ6B1i-FPIM1tP1-pLU5cpJXnNp9TP0wx--2eIug6CmlB0cofdthgSFr2Yd9mBru6x40WF--dyBy_BZHWa4_Jj9vOvrCCoc5DQUso6OTnop0cDwlZAGAjZkBlDuiLa-utO4a610iCrDIquhVKukRj50HSoeLmFqm6ukuFTWTeU8a6hqMDMAIQNYvRSQrqDi-JyW2RgPgfK2_fL_vX9B51o6BL_oG3BVH9SG4Wu2d1nZyevPi9Xjh3a4KhAxJ2j3VBKnaMiRMxlJCKeRwTCglC5PBJcIMRAUMFV6GVc-ypXSBbzLMefhYpl8ICNKhTxEQMhYyUyL0fMosJ5FsQawYSb-mheuEvT6ZiFg54SZTua02CNi2RIXVsnVr0JqRd3Owmqd8yme7ZN39LjJoZ4MILkim0mGHZuYn0-GE2C65YuY2Sl622bUIdUcy0ZXU_jm_ZBQcz5mD3sLW4vMQIrBLuuePz_wj1ht_DJHig9ZaOu2epnCLG6dMIOp9-8CS6k5cd3HyZ2Qf0GXg0tIQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF6V9AAXBBRo-B0kxM2JEzve3WNUUaW0zYVW6m21Xq-Fo9oOtiORG-_AA_EuPAkzaztQiaoSR9sz8soznvlmd34Ye8_D1MToijwZ2KmHBs_3BHoZL0qCKKYxk35I9c7ny2hxGX66ml3tsaO-FobSKjvb39p0Z627O-Pua47XWTb-PKHW7AgIJjT4Bt3sPbYfzjDaG7D9-cnpYrk7TOC-O2gmeo8Y_hTyjFejlflSlXlMSV6zEfXzdIPf_umiboOgzhUdP2IPOwwJ83aZj9meLZ6wg3mB8XO-hQ_gsjrddvkB-_lXVhCUKWioKWWdjBy006MBYSsgDISkz4whWRFt-W1rMGotLOgigaypIdcrJEY-VB0qXq6hKKubZHiVlxVlvFvICnAzAGGNGD3XEG_hOvu6yRJwnwPX2_bL_vX9B-1o2BxfUNfgqj-pjUJTbZ-yy-OPF0cLrxva4JlAisazfqi1TQMZScF1JCOeRgTCgtD4PJJcIsRAUMFNOEm4nZrUIJngSYqPpRE6eMYGBS7xkIHUwshkkiJmMeEsCYRFMOHHU1QvjNJsPGRhLydluo7mNFjjWvWpayvViVeReDHaUSjeIRvt2NZtS4-7GESvBOqGbip0O3exvuuVRuF_S4cxurDlplbUIdUdS0a300xd-6BAcD5kz1uN260YgRWCXV---P_FvWX3FxfnZ-rsZHn6kj3AJ93m0is2aKqNfY1wq4nfdL_TbySbLXs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+sensitive+method+for+the+determination+of+oxycodone+and+its+major+metabolites+noroxycodone+and+oxymorphone+in+human+plasma+by+liquid+chromatography-tandem+mass+spectrometry&rft.jtitle=Journal+of+chromatography.+B%2C+Analytical+technologies+in+the+biomedical+and+life+sciences&rft.au=Gaudette%2C+Fleur&rft.au=Sirhan-Daneau%2C+Andr%C3%A9a&rft.au=St-Onge%2C+Maude&rft.au=Turgeon%2C+Jacques&rft.date=2016-01-01&rft.issn=1873-376X&rft.eissn=1873-376X&rft.volume=1008&rft.spage=174&rft_id=info:doi/10.1016%2Fj.jchromb.2015.11.035&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1570-0232&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1570-0232&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1570-0232&client=summon |